KDR and gastric cancer: After progression of disease from first line, taxanes (mainly paclitaxel) and irinotecan have been shown to be effective and tolerable [2], while ramucirumab, a human IgG1 monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR2), alone or in combination with paclitaxel has statistically increased survival for GC patients [3, 4].